The anti-leukemia effects of thioridazine were also tested in vivo, where the treatment significantly reduced the progression of tumor growth in t (6;11) SHI-1 cell transplanted mice, but not in mice transplanted with t (5;17) HL60 or t (9;11) THP-1 cells, highlighting the specificity of thioridazine against cells with the MLL-AF6 fusion. This evidence concerns the gene KMT2A and leukemia.